Revvity Inc
XMUN:PKN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
R
|
Revvity Inc
XMUN:PKN
|
US |
|
F
|
First Advantage Corp
F:0MS
|
US |
|
CloudMD Software & Services Inc
F:6PH
|
CA |
|
P
|
Pinnacle West Capital Corp
LSE:0KIT
|
US |
Intrinsic Value
Is PKN undervalued or overvalued?
See the intrinsic value estimate for Revvity Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Revvity Does
Revvity makes tools and tests used in laboratories that study biology and diagnose disease. Its products include laboratory instruments, reagents, assay kits, software, and related services that help customers measure biological signals, run genetic and biochemical tests, and analyze results. The company serves drug developers, biotech and academic research labs, and clinical and public health laboratories.
- Headquarters
- United States of America US
- Employees
- 11 000
- IPO date
- Jul 6, 1965
Revvity has no economic moat
Customers can choose among many suppliers because research tools and diagnostic products compete on price, service, technology, availability, quality and reliability—not because a supplier’s product becomes more valuable as more labs use it. Revvity’s patents and product names support particular offerings, but its disclosures do not show a company-wide lock on customers or a brand premium that keeps rivals from competing.
Read the full moat analysis
Revenue & Expenses Breakdown
Revvity Inc
Earnings Waterfall
Revvity Inc
The intrinsic value for Revvity Inc (PKN) under the Base Case is hidden EUR.
Compared with the current market price of 144.6 EUR, the stock appears hidden.